Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. on October 13, 2020. The filing reports changes to the agenda of the Company's Annual General Meeting (AGM) scheduled for November 1, 2020, in Bnei Brak, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and meeting logistics rather than financial performance.
Material Changes
- Board Composition: Sivan Rahamin will resign as an external director on October 19, 2020, to become CEO of a Fintech company.
- New Director Nomination: Proposal 7 nominates Yali Sheffi to serve as an external director for a three-year term, including details on remuneration and option grants.
- Compensation Grant: Proposal 8 grants options to purchase American Depositary Shares (ADS) to elected external director Jonathan Burgin, subject to the approval of Proposal 7.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on business outlook, or specific risk factors. The primary contingency noted is the shareholder vote required to approve the new director nomination and the associated option grants at the upcoming AGM.
Key Facts for Investor Verification
- Verify the outcome of the shareholder vote on Proposal 7 (Yali Sheffi's nomination) and Proposal 8 (Jonathan Burgin's option grant) at the November 1, 2020 AGM.
- Confirm the effective date of Sivan Rahamin's resignation as external director (October 19, 2020).
- Review the attached revised Notice and Proxy Statement (Exhibit 99.1) for full details on director remuneration and option terms.